title: [Dose-response relation of gallopamil in comparison with nifedipine, diltiazem and tiapamil in patients with coronary heart disease].
abstract: For effective treatment of coronary heart disease with calcium antagonists, knowledge of both the dose-response relationship of a remedy and equipotent dosage for comparison of different drugs is necessary. We performed controlled studies to evaluate the influence of single oral doses of calcium antagonists on ischemic ST-depression (calculated as the mean of all exercise and recovery minutes = mean ST-depression) in exercise ECGs of patients with proven CHD and stable angina pectoris. Ergometries were carried out under constant conditions, particularly with individually constant work load and duration. All calcium antagonists reduced ischemic ST-depression during ergometry dose-dependent when compared to placebo. Diltiazem: 90 mg: 6% (n.s.), 120 mg: 19% (n.s.) und 180 mg: 26% (p less than 0.025); gallopamil: 25 mg: 19% (n.s.), 50 mg: 34% (p less than 0.01) und 100 mg: 57% (p less than 0.0025); nifedipine-Cps.: 5 mg: 17%, 10 mg: 33% und 20 mg: 42%; nifedipine-Tbl.: 20 mg: 8% (p less than 0.05), 40 mg: 23% (p less than 0.057 und 60 mg: 31% (p less than 0.05); tiapamil: 300 mg: 30% (p less than 0.05) und 600 mg: 60% (p less than 0.01). As the result of our findings, comparable antiischemic effects can be expected with 120 mg diltiazem, 50 mg gallopamil, 20 mg nifedipin as capsule or 60 mg nifedipin as tablet and 600 mg tiapamil.
authors.affiliation: Abteilung für Kardiologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt.
authors.forename: R
authors.initials: R
authors.lastname: Hopf
authors.forename: K
authors.initials: K
authors.lastname: Fleischer
authors.forename: A
authors.initials: A
authors.lastname: Forster
authors.forename: C
authors.initials: C
authors.lastname: Mohler
authors.forename: P C
authors.initials: PC
authors.lastname: Schulz
authors.forename: M
authors.initials: M
authors.lastname: Kaltenbach
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D004110:Diltiazem / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects*; D005080:Exercise Test / Q000187:drug effects*; D005711:Gallopamil / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage*; D011437:Propylamines / Q000008:administration & dosage*; D013976:Tiapamil Hydrochloride
chemical_list: D002121:Calcium Channel Blockers; D011437:Propylamines; D005711:Gallopamil; D004110:Diltiazem; D009543:Nifedipine; D013976:Tiapamil Hydrochloride
vernacular_title: Dosis-Wirkungsbeziehung von Gallopamil im Vergleich zu Nifedipin, Diltiazem und Tiapamil bei Patienten mit koronarer Herzkrankheit.